Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 7/20 | 0.53 |
| ▸ | DDR1 | Q08345 | 9/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15161526 | 0.92 | CCR2 (0.50) | CCR2DDR1MAPK9MAPK10BCL2 | |
| SCHEMBL8353863 | 0.88 | CCR2 (0.46) | CCR2DDR1 | |
| SCHEMBL3547611 | 0.86 | ALDH1A1 (0.49) | CCR2DDR1BCL2BCL2L1 | |
| SCHEMBL3480241 | 0.82 | MAPK9 (0.46) | CCR2MAPK9MAPK10 | |
| SCHEMBL3545198 | 0.81 | CCR2 (0.54) | CCR2DDR1 | |
| SCHEMBL3546787 | 0.80 | CCR2 (0.48) | CCR2MAPK9MAPK10BCL2BCL2L1 | |
| SCHEMBL3545167 | 0.79 | ALDH1A1 (0.50) | CCR2DDR1 | |
| SCHEMBL3480186 | 0.77 | MAPK9 (0.49) | MAPK9MAPK10 | |
| SCHEMBL3546605 | 0.77 | CCR2 (0.51) | CCR2MAPK9MAPK10 | |
| SCHEMBL3540714 | 0.76 | MEN1 (0.43) | BCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683078-B2 | Arylsulfonamide derivatives as C-Jun-N-Terminal Kinases (JNK's) inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-03-23 | — | — | US | claimed |
| US-20040248886-A1 | Pharmaceutically active sulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors | MERCK SERONO SA (CH) | 2004-12-09 | — | — | US | claimed |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
| US-7683078-B2 | Arylsulfonamide derivatives as C-Jun-N-Terminal Kinases (JNK's) inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-03-23 | — | — | US | disclosed |
| US-7683078-B2 | Arylsulfonamide derivatives as C-Jun-N-Terminal Kinases (JNK's) inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-03-23 | — | — | US | disclosed |
| US-7683078-B2 | Arylsulfonamide derivatives as C-Jun-N-Terminal Kinases (JNK's) inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-03-23 | — | — | US | disclosed |
| US-20100029719-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029719-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029719-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-1409483-B1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | SERONO LAB (CH) | 2008-12-31 | — | — | EP | disclosed |
| US-20040248886-A1 | Pharmaceutically active sulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors | MERCK SERONO SA (CH) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248886-A1 | Pharmaceutically active sulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors | MAPK1, MAPK3, MAP3K2 | CCR2 247/4885DDR1 3412/4885MAPK9 28/4885 |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | CCR2 471/4885DDR1 3680/4885MAPK9 1/4885 |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | MAPK9, IAPP, RNASE1 | CCR2 471/4885DDR1 3680/4885MAPK9 1/4885 |
| US-20100029719-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | MAPK1, MAPK3, MAP3K2 | CCR2 379/4885DDR1 3079/4885MAPK9 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.